Hepatitis C virus genotypes: Clinical relevance and therapeutic implications

Chang Gung Medical Journal

Volumn 31, Issue 1, 2008, Pages 16-25

  Lee, Chuan Mo ^a,b,c   Hung, Chao ^a   Lu, Sheng Nan ^a   Changchien, Chi Sin ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b Department of Chinese Medicine ^*

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Clinical relevance; Hepatitis C virus genotype; Host factor; Interferon; Ribavirin; Therapeutic implication

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; INTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN;

ANTIVIRAL THERAPY; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEREDITY; HUMAN; LIVER CELL CARCINOMA; MONOTHERAPY; PREDICTOR VARIABLE; PREVALENCE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER NEOPLASMS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 41449090219     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14.
2. Hasan F, Jeffers LJ, De Medina M, Reddy KR, Parker T, Schiff ER, Houghton M, Choo QL, Kuo G. Hepatitis C-associated hepatocellular carcinoma. Hepatology 1990;12:589-91.
3. Poynard T, Bedossa P, Oplon P; for the OBSTIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrous progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
4. Lee CM, Lu SN, Changchien CS, Yeh CT, Hsu TT, Tang JH, Wang JH, Lin DY, Chen CL, Chen WJ. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999;86:1143-50.
5. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987;47:4967-72.
6. Taylor-Robinson SD, Foster GR, Arora S, Gargreaves S, Thomas HC. Increase in primary liver cancer in the UK 1979-1994. Lancet 1997;350:1142-3.
7. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-23.
8. Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Chen CH. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 2006;119:1946-52.
9. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62S-5S.
10. Darwish MA, Raouf TA, Rushdy P, Constantine NT, Rao MR, Edelman R. Risk factors associated with a high sero-prevalence of hepatitis C virus infection in Egyptian blood donors. Am J Trop Med Hyg 1993;49:440-7.
11. Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, Yang PM, Hsu HM, Chang MH, Chen CJ, Hahn, LC, Choo QL, Wang TH, Houghton M. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990;162:817-22.
12. Sheu JC, Wang JT, Wang TH, Wang CY, Yang PM, Huang GT, Shih LN, Lee HS, Chen DS. Prevalence of hepatitis C viral infection in a community in Taiwan. Detection by synthetic peptide-based assay and polymerase chain reaction. J Hepatol 1993;17:192-8.
13. Lu SN, Chue PY, Chen HC, Wu MH, Chen IL, Huang JF, Wang JH, Peng CF, Shih CH, You SL, Lu CF, Chen CJ, Chang WY. Different viral aetiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan. J Gastroenterol Hepatol 1997;12:547-50.
14. Wang JH, Lu SN, Wu JC, Huang JF, Yu ML, Chen SC, Chuang WL. A hyperendemic community of hepatitis B virus and hepatitis C virus infection in Taiwan. Trans R Soc Trop Med Hyg 1999;93:253-4.
15. Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, Coit D, Medina-Selby R, Barr PJ, Weiner AJ, Bradley DW, Kuo G, Houghton M. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991;15:2451-5.
16. Brown EA, Zhang H, Ping LH, Lemon SM. Secondary structure of the 5′ nontranslated regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res 1992 11;20:5041-5.
17. Simmonds P. Clinical relevance of hepatitis C virus genotypes. Gut 1997;40:291-3.
18. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-73.
19. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C; Collaborative Study Group. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995;122:161-8.
20. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, Cobain TJ, Krusius T, Kolho E, Naukkarinen R. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994;32:884-92.
21. Kao JH, Chen PJ, Lai MY, Yang PM, Sheu JC, Wang TH, Chen DS. Genotypes of hepatitis C virus in Taiwan and the progression of liver disease. J Clin Gastroenterol 1995;21:233-7.
22. Lee CM, Lu SN, Hung CH, Tung WC, Wang JH, Tung HD, Chen CH, Hu TH, Changchien CS, Chen WJ. Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications. Trans R Soc Trop Med Hyg 2006;100:767-74.
23. Yu ML, Chuang WL, Chen SC, Dai CY, Hou C, Wang JH, Lu SN, Huang JF, Lin ZY, Hsieh MY, Tsai JF, Wang LY, Chang WY. Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. J Med Virol 2001;65:58-65.
24. Agha S, Tanaka Y, Saudy N, Kurbanov F, Abo-Zeid M, El-Malky M, Khalaf M, Ohta N, Yoshizawa H, Mizokami M. Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: a collaborative study between Japan, Egypt, and Uzbekistan. J Med Virol 2004;73:216-22.
25. Tong MJ, Sun SC, Schaeffer BT, Chang NK, Lo KJ, Peters RL. Hepatitis-associated antigen and hepatocellular carcinoma in Taiwan. Ann Intern Med 1971;75:687-91.
26. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.
27. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002;2:395-403.
28. Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, Tanaka E. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004;127:S17-26.
29. Okuda K. Hepatocellular carcinoma. J Hepatol 2000;32:225-37.
30. Shibuya K, Yano E. Regression analysis of trends in mor-tality from hepatocellular carcinoma in Japan. Int J Epidemiol 2005;34:397-402.
31. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127:1372-80.
32. Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1996;8:324-8.
33. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002;36:S1-2.
34. APASL Hepatitis C Working Party. APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:615-33.
35. Jarvis LM, Ludlam CA, Ellender JA, Nemes L, Field SP, Song E, Chuansumrit A, Preston FE, Simmonds P. Investigation of the relative infectivity and pathogenicity of different hepatitis C virus genotypes in hemophiliacs. Blood 1996;87:3007-11.
36. Chen CH, Sheu JC, Wang JT, Huang GT, Yang PM, Lee HS, Lee CZ, Chen DS. Genotypes of hepatitis C virus in chronic liver disease in Taiwan. J Med Virol 1994;44:234-6.
37. Ikeda K, Kobayashi M, Someya T, Saitoh S, Tsubota A, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H. Influence of hepatitis C virus subtype on hepatocellular carcinogenesis: A multivariate analysis of a retrospective cohort of 593 patients with cirrhosis. Intervirology 2002;45:71-8.
38. Reid AE, Koziel MJ, Aiza I, Jeffers L, Reddy R, Schiff E, Lau JY, Dienstag JL, Liang TJ. Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States. Am J Gastroenterol 1999;94:1619-26.
39. Yotsuyanagi H, Koike K, Yasuda K, Moriya K, Hino K, Kurokawa K, Iino S. Hepatitis C virus genotypes and development of hepatocellular carcinoma. Cancer 1995;76:1352-5.
40. Mizokami M, Tanaka Y, Miyakawa Y. Spread times of hepatitis C virus estimated by the molecular clock differ among Japan, the United States and Egypt in reflection of their distinct socioeconomic backgrounds. Intervirology 2006;49:28-36.
41. Hassan MM, Hwang LY, Hatten CJ, Swaim M. Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206-13.
42. Fattovich G, Stroffolini T, Zagni I, Donato F. Cirrhosis and hepatocellular carcinoma: incidence and factors related to development of hepatocellular carcinoma. Gastroenterology 2004;127:S35-50.
43. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okuda M, Hino K, Okita K; Osaka Liver Disease Study Group. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-402.
44. Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, Chen CH, Chen WJ, Changchien CS. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat 2006;13:409-14.
45. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24.
46. Hung CH, Kuo FY, Wang JH, Lu SN, Hu TH, Chen CH, Lee CM, Eng HL. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy. Antivir Ther 2006;11:483-9.
47. Omata M, Yoshida H. Resolution of liver cirrhosis and prevention of hepatocellular carcinoma by interferon therapy against chronic hepatitis C. Scand J Gastroenterol Suppl 2003;237:47-51.
48. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
49. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, Cipolla A, Fabbri C, Pezzoli A, Roda E. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-7.
50. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998;28:1121-7.
51. Hino K, Kitase A, Satoh Y, Fujiwara D, Yamaguchi Y, Korenaga M, Shingai Y, Konishi T, Yamashita S, Uchida K, Mori K, Hanada H, Kodama T, Nukui K, Okita K. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepat 2002;9:370-6.
52. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, Bourliere M, Boucher E, Miguet JP, Parlier D, Lemonnier C, Opolon P. Treatment of hepatitis C virus related cirrhosis: a randomized controlled trial of interferon alfa 2b versus no treatment. Hepatology 1999;29:1870-5.
53. Baffis V, Shrier I, Sherker AH, Szilagvi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med 1999;131:696-701.
54. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, Nishioji K, Murakami Y, Kashima K; Viral Hepatitis Therapy Study Group. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol 1999;30:653-9.
55. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001;15:89-98.
56. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001;34:593-602.
57. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A , Weiland O. Randomized, double blind, placebo-controlled trial of interferon alfa 2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-7.
58. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomized trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
59. McHutchinson JG, Gordon SC, Schiff ER, Schiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
60. Schalm SW, Weiland O, Hansen BE, Miella M, Lai MY, Hollander A, Michielsen PP, Bellobuono A, Chemello L, Pastore G, Chen DS, Brouwer JT. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 1999;117:408-13.
61. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
62. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
63. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006;11:985-94.
64. Hepatitis C long-term treatment against cirrhosis. http://www.haltctrial. org.
65. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
66. Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, Chiu CF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. A randomised study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-9.
67. Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, Chang WY, Chang TT, Hsieh TY, Liu CJ, Chen DS. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005;12:283-91.
68. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kuroda H, Tanaka N, Arakawa Y, Omata M; Tokyo-Chiba Hepatitis Research Group. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997;113:558-66.
69. Pagliaro L, Craxi A, Cammaa C, Tine F, Di Marco V, Lo Iacono O, Almasio P. Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994;19:820-8.
70. Lin R, Liddle C, Byth K, Farrell GC. Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C. J Viral Hepat 1996;3:85-96.
71. Hung CH, Lee CM, Lu SN, Wang JH, Chen CH, Hu TH, Kee KM, Chang KC, Tseng PL, Yen YH, Changchien CS. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int 2006;26:1079-86.
72. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH; Collaborative Study Group. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med 1996;125:634-9.
73. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005;3:S97-101.
74. Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir Ther 2005;10:1-11.
75. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-60.
76. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
77. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77-81.
78. Khorsi H, Castelain S, Wyseur A, Izopet J, Canva V, Rombout A, Capron D, Capron JP, Lunel F, Stuyver L, Duverlie G. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol 1997;27:72-7.
79. Squadrito G, Orlando ME, Cacciola I, Rumi MG, Artini M, Picciotto A, Loiacono O, Siciliano R, Levrero M, Raimondo G. Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection. J Hepatol 1999;30:1023-7.
80. Hung CH, Lee CM, Lu SN, Lee JF, Wang JH, Tung HD, Chen TM, Hu TH, Chen WJ, Changchien CS. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepat 2003;10:87-94.
81. Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y, Kurosaki M, Ueda E, Tanabe Y, Maekawa S, Itakura J, Watanabe H, Kakinuma S, Watanabe M. Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. J Gastroenterol Hepatol 2005;20:1401-9.
82. Watanabe K, Yoshioka K, Yano M, Ishigami M, Ukai K, Ito H, Miyata F, Mizutani T, Goto H. Mutations in the nonstructural region 5B of hepatitis C virus genotype 1b: their relation to viral load, response to interferon, and the nonstructural region 5A. J Med Virol 2005;75:504-12.
83. Sugihara K, Orito E, Tanaka Y, Kato T, Lau JY, Ohno T, Hayashi K, Ogino M, Hirashima N, Sakakibara K, Mizuno Y, Kato H, Suzuki S, Ueda R, Mizokami M. Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype lb infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy. Intervirology 2006;49:319-26.
84. Sarrazin C, Berg T, Weich V, Mueller T, Frey UH, Zeuzem S, Gerken G, Roggendorf M, Siffert W. GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection. J Hepatol 2005;43:388-93.
85. Dai CY, Chuang WL, Chang WY, Chen SC, Lee LP, Hsieh MY, Hou NJ, Lin ZY, Huang JF, Hsieh MY, Wang LY, Yu ML. Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. J Infect Dis 2006;193:98-101.
86. Lee CM, Kee KM, Hung CH, Eng HL, Chang CH, Huang CM, Wang JH, Hu TH, Lu SN, Changchien CS, Chen WJ. Hepatic interferon receptor mRNA expression: clinical relevance and its relationship with effectiveness of interferon plus ribavirin therapy in patients with genotype 1b hepatitis C virus infection. Antivir Ther 2006;11:17-23.
87. Hwang Y, Chen EY, Gu ZJ, Chuang WL, Yu ML, Lai MY, Chao YC, Lee CM, Wang JH, Dai CY, Shian-Jy Bey M, Liao YT, Chen PJ, Chen DS. Genetic predisposition of responsiveness to therapy for chronic hepatitis C. Pharmacogenomics 2006;7:697-709.
88. Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Kaneko S. Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. Hepatology 2006;44:1122-38.
89. Ward DG, Cheng Y, N'Kontchou G, Thar TT, Barget N, Wei W, Billingham LJ, Martin A, Beaugrand M, Johnson PJ. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J Cancer 2006 30;94:287-92.
90. Paradis V, Asselah T, Dargere D, Ripault MP, Martinot M, Boyer N, Valla D, Marcellin P, Bedossa P. Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. Gastroenterology 2006;130:2189-97.
91. Koev G, Dekhtyar T, Han L, Yan P, Ng TI, Lin CT, Mo H, Molla A. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro. Antiviral Res 2007;73:78-83.
92. Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, Fiscella M, Yu R, Osborn BL, Cronin PW, Freimuth WW, McHutchison JG, Subramanian GM. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006;44:671-8.
93. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005;41:275-9.